Advances in the use of IVIg in neurological disorders.
Hughes
Richard
R
Cochrane Neuromuscular Disease Review Group, Department of Clinical Neuroscience, King's College London, Guy's Hospital, London, SE1 1UL, UK. richard.a.hughes@kcl.ac.uk
D020274:Autoimmune Diseases of the Nervous System / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy; D009422:Nervous System Diseases / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology; D018579:Patient Selection; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000188:drug therapy; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous